As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the ...

Amneal Pharmaceuticals has agreed to pay $272.5 million to settle approximately 900 lawsuits brought by state, local and ...

Targeting a major pharmaceutical market in retinal diseases, EyePoint Pharmaceuticals has revealed that its lead drug ...

Neurocrine Biosciences, maker of the first drug approved by the FDA to treat tardive dyskinesia, continues to throw its ...

Zydus Lifesciences recently received its second Form 483 reprimand from the FDA within the span of one month. In the second ...

Gene therapies can correct diseases at their genetic core, but their success hinges on viral vector manufacturing. As gene ...

In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initi | ...

Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio ...

Kirk Harmon, Vice President and General Manager, Contract Sales Organization, IQVIA Jave Castillo, Vice President, CSO Solutions, IQVIA Whether you call them “established,” “mature,” “in-line,” or ...

Novo Nordisk is facing fierce competition from Eli Lilly’s obesity rival Zepbound, which has shaken up U.S. pricing dynamics ...

Physicians are unequivocal about who is the big kahuna in the vaccine industry. | Physicians are unequivocal about who is the ...

With its newly launched predictive analytics platform, Real Chemistry is hoping to “shine a light” on the GLP-1 agonist ...